← All trials
NCT05464745
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2021
- Primary completion
- Jun 9, 2021
- Completion date
- Jun 9, 2021
- First posted
- Jul 19, 2022
- Last posted
- Jul 19, 2022
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Darnitsa Pharmaceutical CompanyLead sponsor
- International Partnership for MicrobicidesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.